SCHEMBL4201721

SCHEMBL4201721

C[Si](C)(C)CCOCn1ccnc1CC(Cc1nccn1COCC[Si](C)(C)C)C(=O)c1ccc(CO)cc1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.34
SLC6A2 P23975 1/20 0.32
SLC6A3 Q01959 1/20 0.32
DGAT1 O75907 3/20 0.31
ALDH1A1 P00352 1/20 0.31
HTT P42858 1/20 0.31
KLKB1 P03952 1/20 0.31
ALPG P10696 2/20 0.31
PLAA Q9Y263 1/20 0.31
AGTR1 P30556 1/20 0.31
AGTR2 P50052 1/20 0.31
F11 P03951 1/20 0.30
MAPT P10636 1/20 0.30
ALPL P05186 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4202743 0.87 MEN1 (0.37) NPC1ALDH1A1ALPGPLAAMAPT
SCHEMBL4213678 0.86 DUT (0.36) DGAT1
SCHEMBL4207000 0.84 DGAT1 (0.33) DGAT1ALDH1A1HTTF11MAPT
SCHEMBL4206991 0.81 KLKB1 (0.33) NPC1DGAT1KLKB1F11MAPT
SCHEMBL4196846 0.80 KLKB1 (0.35) NPC1DGAT1KLKB1AGTR1AGTR2
SCHEMBL4200241 0.79 CYP19A1 (0.31)
SCHEMBL2647731 0.77 DGAT1 (0.36) NPC1DGAT1ALDH1A1HTTKLKB1
SCHEMBL4203823 0.76 DGAT1 (0.33) DGAT1
SCHEMBL4203399 0.76 DGAT1 (0.33) DGAT1
SCHEMBL3840178 0.74 ARG1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871210-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-10-28 US disclosed
US-20140072576-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-13 US disclosed
US-8614323-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-12-24 US disclosed
EP-2657235-A1 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-10-30 EP disclosed
EP-1942108-B1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-09-04 EP disclosed
US-20120328627-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-12-27 US disclosed
US-8318931-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-11-27 US disclosed
US-8293896-B2 2012-10-23 US disclosed
US-20090118279-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-05-07 US disclosed
EP-1942108-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140072576-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR1, CXCR3 NPC1 676/4885SLC6A2 674/4885SLC6A3 385/4885
US-20090118279-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF CXCR4, CXCR1, CXCR3 NPC1 542/4885SLC6A2 523/4885SLC6A3 280/4885
US-20120328627-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR1, CXCR3 NPC1 676/4885SLC6A2 674/4885SLC6A3 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.